AIZ
66
-2
CMCSA
39
-2
RSG
62
-2
LEN
45
3
ADP
59
-2
MAT
39
-6
PBI
59
-7
UHS
52
2
MUR
34
-10
AIV
65
-6
ALL
41
6
AAP
29
-3
A
39
-2
FSLR
63
5
CFG
46
2
T
48
3
MAS
52
-2
SLG
57
4
PNC
53
-2
IVZ
50
-5
AIZ
66
-2
CMCSA
39
-2
RSG
62
-2
LEN
45
3
ADP
59
-2
MAT
39
-6
PBI
59
-7
UHS
52
2
MUR
34
-10
AIV
65
-6
ALL
41
6
AAP
29
-3
A
39
-2
FSLR
63
5
CFG
46
2
T
48
3
MAS
52
-2
SLG
57
4
PNC
53
-2
IVZ
50
-5
Financhill
Back

BioXcel Therapeutics 10K Form

Sell
31

BTAI
BioXcel Therapeutics

Last Price:
0.41
Seasonality Move:
80.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BTAI News And Ratings

See the #1 stock for the next 7 days that we like better than BTAI

BTAI Financial Statistics

Sales & Book Value

Annual Sales: $1.38M
Cash Flow: $-16.34M
Price / Cash Flow: 0
Annual Sales: $-2.02
Price / Book: 0

Profitability

EPS (TTM): -2.16000
Net Income (TTM): $-71M
Gross Margin: $120K
Return on Equity: 0%
Return on Assets: -95.73%

BioXcel Therapeutics Earnings Forecast

Key BioXcel Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 3 years for BTAI is 8.70%.
  • The Selling, General & Administrative Expenses for BTAI have been equal to 6,044.42% of Gross Profit Margin.
  • The Research & Development expenses have been 6,110.58% of Revenue.
  • The Interest Expense is -7.44% of Operating Income.
  • The Net Earning history of BTAI is -12,974.86% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 0 years.

BioXcel Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BTAI
CUSIP: 09075P
Website: bioxceltherapeutics.com

Debt

Debt-to-Equity Ratio: -1.22
Current Ratio: 1.87
Quick Ratio: 1.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BTAI Technical Analysis vs Fundamental Analysis

Sell
31
BioXcel Therapeutics (BTAI) is a Sell

Is BioXcel Therapeutics a Buy or a Sell?